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Abstract
Background: Previous studies have evidenced an association between gastroesophageal reflux and esophageal
adenocarcinoma (EA). It is unknown to what extent these associations vary by population, age, sex, body mass index,
and cigarette smoking, or whether duration and frequency of symptoms interact in predicting risk. The Barrett’s and
Esophageal Adenocarcinoma Consortium (BEACON) allowed an in-depth assessment of these issues.
Methods: Detailed information on heartburn and regurgitation symptoms and covariates were available from five BEACON
case-control studies of EA and esophagogastric junction adenocarcinoma (EGJA). We conducted single-study multivariable
logistic regressions followed by random-effects meta-analysis. Stratified analyses, meta-regressions, and sensitivity analyses
were also conducted.
Results: Five studies provided 1,128 EA cases, 1,229 EGJA cases, and 4,057 controls for analysis. All summary estimates
indicated positive, significant associations between heartburn/regurgitation symptoms and EA. Increasing heartburn
duration was associated with increasing EA risk; odds ratios were 2.80, 3.85, and 6.24 for symptom durations of ,10 years,
10 to ,20 years, and $20 years. Associations with EGJA were slighter weaker, but still statistically significant for those with
the highest exposure. Both frequency and duration of heartburn/regurgitation symptoms were independently associated
with higher risk. We observed similar strengths of associations when stratified by age, sex, cigarette smoking, and body
mass index.
Conclusions: This analysis indicates that the association between heartburn/regurgitation symptoms and EA is strong,
increases with increased duration and/or frequency, and is consistent across major risk factors. Weaker associations for EGJA
suggest that this cancer site has a dissimilar pathogenesis or represents a mixed population of patients.
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Introduction
The association between gastroesophageal reflux and inflam-
mation of the distal esophageal mucosa was first expounded by
Winkelstein in 1935 [1]. Barrett himself acknowledged that
gastroesophageal reflux may be a cause of the eponymously titled
metaplastic lesion that precedes adenocarcinoma [2], and future
human observations [3] and animal experiments [4] were to
provide evidence for such. Concurrent with these developments
was the proposition, derived from clinical observation, that
gastroesophageal reflux may predispose to cancer of the distal
esophagus [5]. Three studies, completed in the 1990s, provided
strong and seminal epidemiologic evidence for this hypothesis [6–
8], and subsequent studies provided confirmatory evidence for the
association between gastroesophageal reflux and adenocarcinomas
of the esophagus [9–12]. However, it is unknown to what extent
these associations vary by population using harmonized adjusted
models. Furthermore, investigations of whether these associations
differ with respect to age, sex, body mass index (BMI), cigarette
smoking, and anti-reflux medications have been limited due to
small numbers upon stratification. Lastly, the interplay between
duration and frequency of exposure with respect to risk of
esophageal adenocarcinomas is unclear. Therefore, we assessed
whether heartburn and regurgitation exposures were associated
with esophageal adenocarcinoma (EA) and esophagogastric
junction adenocarcinoma (EGJA) by pooling, harmonizing, and
analyzing detailed individual participant data from five case-
control studies in the international Barrett’s and Esophageal




The BEACON consortium was formed in 2005 with support
from the U.S. National Cancer Institute. It is composed of
investigators from around the world and brings together popula-
tion-based case-control and cohort studies of Barrett’s esophagus,
EA and EGJA. The primary objectives of BEACON are to
facilitate well-powered, combined investigations of risk factors in
relation to these diseases, as well as aid in the development of new
studies of etiology, prevention and survival.
Twelve BEACON studies included in a pooled analysis of
tobacco smoking in relation to adenocarcinomas of the esophagus
have been described previously [13]. Five of these studies were
able to provide information on heartburn and regurgitation
exposures: the nationwide Australian Cancer Study (Esophageal
Cancer Component) [11]; FINBAR (Factors INfluencing the
Barrett’s/Adenocarcinoma Relationship) study, based in Ireland
[12]; Los Angeles County Multi-ethnic Case–control Study [14]; a
nationwide Swedish study of esophageal cancer and esophagogas-
tric junction adenocarcinoma [15]; and the United States (US)
Multi-center Study [16] (See File S1 for further details).
In combination, these five studies provided 1,197 EA cases,
1,317 EGJA cases, and 4,711 population-based controls. We
restricted the analytic population to white non-Hispanics, due to
the relatively small number of non-White, non-Hispanic case
patients (17 Black, 101 Hispanic, 39 other race or ethnic groups).
After these exclusions there remained 1,128 EA cases, 1,229 EGJA
cases, and 4,057 controls for analysis. Data acquisition and data
pooling for each study were approved by the Institutional Review
Board or Research Ethics Committee of the institute(s) sponsoring
each study.
Study Variables
Self-reported questionnaires were administered at or near the
time of cancer diagnosis for case patients and at time of
recruitment for control subjects. The two primary exposures for
the study were symptoms of heartburn and regurgitation.
Heartburn symptoms related to burning or aching pain behind
the breastbone/sternum not due to heart problems, and regurgi-
tation symptoms were commonly specified as a sour taste resulting
from regurgitation of acid, bile or other stomach contents into the
mouth. The questions used by each study to ascertain these
exposures are shown in Table 1 in File S1. Heartburn and
regurgitation symptoms were harmonized as recurrent/not
recurrent (dichotomous using a frequency of weekly or greater
for ‘recurrent’), categories of duration of exposure (0, 1–9, 10–19,
20+ years) and categories of frequency of exposure (never, ,
monthly, monthly to ,weekly, weekly to ,daily, $daily). The
term GERD (gastroesophageal reflux disease) will be used to refer
to the combined exposure of heartburn or regurgitation. This
combined exposure was assessed given that heartburn and
regurgitation symptoms essentially reflect a similar exposure;
namely the exposure of the esophagus to gastric juice.
Other variables included in our analyses were age, sex,
education, BMI (weight divided by square of height [kg/m2]),
cigarette smoking, alcohol consumption, use of proton pump
inhibitors, H2 receptor antagonists, antacids, any anti-reflux
medications (catch-all variable), and non-steroidal anti-inflamma-
tory drugs, as well as study-specific variables (study center for US
Multi-center Study and country of birth for Los Angeles County
Multi-ethnic Case–control Study).
Statistical Analysis
We used a two-step analytic approach. First, we used
multivariable logistic regression models to estimate study-specific
odds ratios (ORs) and 95% confidence intervals (CIs) of the
association between exposure and outcome in each study. Second,
the study-specific ORs were pooled using random-effects meta-
analysis to generate summary ORs [17]. We excluded study-
specific results from a particular meta-analysis if the underlying
model from that study failed to converge.
Study-specific, minimally adjusted logistic regression models
included the covariates age (categorical: ,50, 50–59, 60–69, $70
years), sex, and study-specific variables (where appropriate). In
each study, we assessed whether any of the following variables
changed pooled or study-specific dichotomous exposure estimates
(ORs) by .10%: BMI, height, recent weight, cigarette smoking,
alcohol consumption, non-steroidal anti-inflammatory drugs,
education, fruit consumption, and vegetable consumption. Only
pack-years of cigarette smoking altered estimates of a single study
(FINBAR) by .10%. However, in addition to those variables
included in the minimally adjusted models, we included the
following covariates in all study-specific maximally adjusted
models given previous evidence of associations between these
exposures and adenocarcinomas of the esophagus: BMI (categor-
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ical: ,25, 25–29.9, $30) [18], education (study-specific) [19,20],
alcohol consumption (categorical: ,7, 7–20, $21 drinks per week)
[21], and cigarette smoking (categorical: 0, 1–14, 15–29, 30–44, $
45 pack-years) [13]. Results were not materially different between
minimally and maximally adjusted models, thus we present only
the latter results.
To investigate potential effect-modification (and between-study
heterogeneity) we conducted analyses of recurrent heartburn and/
or recurrent regurgitation stratified analyses by age (,60, 60–69,
$70 years), sex (male/female), cigarette smoking (ever/never), and
BMI (,25, 25–29, $30) as these are known risk factors for
esophageal adenocarcinomas. The statistical significance of
potential effect-modifiers was assessed by a two-step analysis of
product-terms using dichotomous (cigarette smoking, sex) or
continuous (age, BMI) variables combined with the primary
exposures of interest. To further investigate between-study
heterogeneity, we also conducted meta-regressions of anti-gastro-
esophageal reflux medications (e.g., proton pump inhibitors, H2
receptor antagonists, antacids, and any anti-reflux medications)
and mid-year of recruitment using the STATA metareg command
with 5,000 Monte Carlo permutations to generate each p value
[22]. A false-discovery rate method was used to control the type I
error [23]. Lastly, we also conducted sensitivity analyses whereby
each study was omitted in-turn with re-estimation of the
association to determine if any single study dominated a summary
OR. The I2 value and its 95% uncertainty interval were used to
estimate the percentage of total variation across studies due to
heterogeneity [24]. An I2 statistic of 0% indicates no observed
heterogeneity, whereas larger values indicate increasing heteroge-
neity. All analyses were performed using STATA software, version
12 (StataCorp LP, College Station, TX). All statistical tests were
two-sided. P values less than 0.05 were considered to be
statistically significant.
Results
Descriptive statistics of Study Populations
There were 1,128 EA cases, 1,229 EGJA cases, and 4,057
controls available for analysis (Table 1). The cases and controls
were predominantly male (66–87%), with a median age of
approximately 65 years old. Cases were more likely than controls
to smoke cigarettes and, of those who did, total exposure was also
greater, using the exposure metric of pack-years of cigarette
smoking. The proportions that reported recurrent (weekly or
greater) heartburn and/or recurrent regurgitation were greatest in
the EA group, then the EGJA group, and lowest amongst the
controls; anti-gastroesophageal reflux medications displayed a
similar pattern.
Heartburn or Regurgitation Exposures
Table 2 shows the relationship between the presence of
recurrent heartburn and/or recurrent regurgitation and risk of
adenocarcinomas of the esophagus. Recurrent heartburn/recur-
rent regurgitation was associated with an approximate 5-fold
statistically significant increased risk of EA. For EGJA, the
associations were also statistically significant albeit slightly weaker
than those for EA at around 2-fold increased risk. Of note was the
moderate-to-high heterogeneity (I2) associated with each summary
risk estimate, with I2s ranging from 47% to 84%.
Associations between increasing duration and frequency of
gastroesophageal reflux in relation to adenocarcinomas of the
esophagus are shown in Tables 3 and 4, respectively, as well as in
Figure 1. Note that these analyses are not restricted to those with









































































































































































































































































































































































































































































































































































































































Reflux and Esophageal Cancer in BEACON



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Reflux and Esophageal Cancer in BEACON











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Reflux and Esophageal Cancer in BEACON
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e103508
evident that as heartburn or regurgitation exposure increases so
does the strength of the association with EA. For example, ORs for
increasing heartburn duration were 2.80 (95%CI: 1.60, 4.91), 3.85
(95%CI: 2.93, 5.07), and 6.24 (95%CI: 3.37, 11.55) for durations
of exposure of ,10 years, 10 to ,20 years, and $20 years,
respectively, all compared with those not experiencing symptoms.
The associations of increasing gastroesophageal reflux exposures
with EGJA were, relative to those for EA, much weaker, but still
statistically significant in a majority of the highest exposure
categories. Heterogeneity was often moderate (,50%) to high
(,75%), but with wide uncertainty intervals. In joint-effects
models of increasing duration and increasing frequency of
gastroesophageal reflux symptoms, it was clear that both factors
play a role in risk of adenocarcinomas of the esophagus with some
indication that frequency may be slightly more important, given
the categorical cut-points assessed (Table 5 and Tables 2–5 in File
S1).
Sensitivity Analyses
Sensitivity analyses demonstrated that the Swedish study was a
major contributor to the heterogeneity in analyses of heartburn in
relation to EA; excluding this study attenuated associations slightly
and also lowered the heterogeneity (ORrecurrent heartburn = 4.04,
95%CI: 3.13, 5.22, I2 = 39%; ORduration category 2 = 2.45, 95%CI:
1.31, 4.60, I2 = 71%; ORduration category 3 = 3.78, 95%CI: 2.75,
5.19, I2 = 0%; ORduration category 4 = 4.75, 95%CI: 3.18, 7.09,
I2 = 54%; ORfrequency category 2 = 0.91, 95%CI: 0.68, 1.21, I
2 = 0%;
ORfrequency category 3 = 2.54, 95%CI: 1.83, 3.53, I
2 = 10%;
ORfrequency category 4 = 3.70, 95%CI: 2.30, 5.96, I
2 = 66%;
ORfrequency category 5 = 5.70, 95%CI: 4.23, 7.67, I
2 = 0%). Exclusion
of this study from the dichotomous recurrent/not recurrent
regurgitation analysis in relation to EA also caused a reduction
in estimated heterogeneity (ORrecurrent regurgitation = 4.16, 95%CI:
3.18, 5.43, I2 = 38%), although its exclusion had minimal impact
on the moderate-to-high heterogeneity detected in the analyses of
regurgitation duration and regurgitation frequency (data not
shown). In analyses of recurrent heartburn and recurrent
regurgitation exposures combined, the US Multi-center Study
was the predominant source of the heterogeneity–although with
exclusion of this study, heterogeneity for a majority of heartburn/
regurgitation results remained at levels considered moderate-to-
high (data not shown) and there was no effect on estimates of
heartburn and regurgitation frequency. Sensitivity analyses of
EGJA did not indicate any predominant source of heterogeneity.
Figure 1. Forest plots of associations between heartburn and regurgitation exposures in relation to case and control groups in
BEACON. A: The association between recurrent heartburn or recurrent regurgitation in relation to esophageal adenocarcinoma. B: The association
between heartburn and regurgitation duration in relation to esophageal adenocarcinoma. C: The association between heartburn and regurgitation
frequency in relation to esophageal adenocarcinoma. D. The frequency of recurrent heartburn or recurrent regurgitation exposure in case and control
groups by study. For each plot each white square represents the study-specific odds ratio (A–C) or prevalence of exposure (D) and the black diamond
represents the overall estimate. The arms of each symbol portray the 95% confidence intervals.
doi:10.1371/journal.pone.0103508.g001
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Effect-modification and Meta-regression Analyses
The only interaction term for effect-modification that was
statistically significant at the nominal level of a= 0.05 was sex
(p = 0.02) in relation to the association between recurrent
heartburn and esophageal adenocarcinoma. Relationships for
EA and EGJA were slightly stronger for women compared with
equivalent estimates for men (Tables 6–11 in File S1). However,
after adjustment for multiple testing using a false-discovery rate
methodology [23], the interaction term was not deemed to be
statistically significant. Although none of the other stratified
analyses provided evidence for effect-modification, the analyses
stratified by BMI suggested some slightly increased risks for the
obese group, relative to normal and overweight groups (Tables
12–20 in File S1). Stratification by age revealed slightly stronger
associations for EA in individuals aged either $60 to ,70 years or
$70 years, compared with individuals aged ,60 years (Tables 21–
29 in File S1). Stratification by cigarette smoking, suggested
slightly elevated associations between recurrent heartburn and EA
for never-smokers (Tables 30–35 in File S1). Meta-regressions of
anti-gastroesophageal reflux medications and of mid-year of
recruitment were not statistically significant after adjustment for
multiple testing. These findings suggest that heterogeneity in the
primary analyses was not solely due to differences in the use of
anti-gastroesophageal reflux medications or to unknown period
effects.
Discussion
This analysis of BEACON data supports a strong positive
association between heartburn and/or regurgitation and increased
risk of adenocarcinomas of the esophagus, as well as positive dose-
response relationships with increasing duration and frequency of
exposure. For EA, all estimates were statistically significant and
suggested that recurrent symptoms of heartburn and/or recurrent
regurgitation was associated with an approximate 5-fold increased
risk of EA. For EGJA the associations were weaker but still
statistically significant. Increasing symptom duration was associ-
ated with greater risk of EA–risks were about 3-fold, 4-fold and 6-
fold higher for symptom durations of ,10 years, 10 to ,20 years,
and $20 years, respectively, all compared with no exposure
(never). Associations between increased frequency/duration of
heartburn/regurgitation with EGJA were weaker, but still
statistically significant for the highest exposed categories. From
joint effects analyses, it was apparent that both increased
frequency and duration of symptoms were associated with higher
risk of EA. Again, equivalent analyses for EGJA exhibited similar,
albeit weaker, associations.
Although statistically significant associations for recurrent
GERD (heartburn or regurgitation) exposure and cancer were
observed separately for each study, there was moderate-to-high
heterogeneity in the magnitude of the observed relative risk
estimates, with the strongest associations often provided by the
Swedish study. This was particularly evident for analyses of
recurrent heartburn in relation to EA. High heterogeneity was also
observed in a recent meta-analysis of gastroesophageal reflux and
EA [10]. The most obvious difference of the Swedish study, which
likely accounts for the more pronounced relationships between
GERD and EA, is the combined consequence of relatively low
recurrent exposure in controls (13%) and relatively high recurrent
exposure in cases (54%) (see Figure 1). The latter is possibly
explained by the fact that the Swedish study was the only study to
define EGJA as adenocarcinoma with its center within 2 cm oral
to, or 3 cm aboral to, the gastroesophageal junction and thus to
exclude cancers ‘‘centered’’ in the most aboral 2 cm of the
esophagus from its definition of esophageal adenocarcinoma [7];
the other included studies defined EA as any adenocarcinoma that
was ‘‘centered’’ above the gastroesophageal junction. Further-
more, the analyses we present here of EGJA suggest these
excluded tumors have a weaker association with GERD. However,
the Swedish study did not provide higher estimates of GERD in
relation to EGJA relative to other studies, although this grouping
of tumors are known to be heterogeneous in their pathogenesis
thus addition of distal EAs to the EGJA case-group may have
limited effects on estimates of association. It is possible that in the
Swedish study population GERD symptoms were differentially
reported, relative to the other included studies, given that the
questionnaire was in Swedish and the word halsbränna refers to a
burning sensation which could occur retrosternally and/or in the
upper throat. When recurrent heartburn and recurrent regurgi-
tation variables were combined, the US Multi-center Study was
the predominant contributor of heterogeneity, although even after
exclusion of this study, heterogeneity remained moderate-to-high
Table 5. Associations between heartburn & regurgitation frequency, duration and esophageal adenocarcinoma and
esophagogastric junction adenocarcinoma.






Never Referent - -
0.1 to ,20 - 3.13 (95%CI: 1.49–6.56; I2 = 84) 4.75 (95%CI: 2.66–8.47; I2 = 72)





Never Referent - -
0.1 to ,20 - 1.92 (95%CI: 0.80–4.59; I2 = 90) 2.20 (95%CI: 1.11–4.37; I2 = 79)
$20 - 1.55 (95%CI: 0.73–3.25; I2 = 59) 2.55 (95%CI: 1.32–4.92; I2 = 76)
Adjusted for age, sex, BMI, education, alcohol consumption, cigarette smoking, and study-specific variables. Abbreviations: CI, confidence interval.
doi:10.1371/journal.pone.0103508.t005
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for most summary estimates. It is conceivable that GERD may
vary in its carcinogenic potency in different populations for
reasons such as genetic background (i.e., gene-environment
interactions) and diet. For example, the composition of refluxate
can affect symptom perception as well as the capacity for mucosal
damage [25] and this may differ geographically.
Associations of heartburn/regurgitation in relation to EGJA
were positive, but not as strong as those observed for EA. A
possible reason for this is that EGJA tumors likely represent a
heterogeneous groups of malignancies–some with a pathogenesis
similar to that of EA and others with a pathogenesis similar to that
of gastric cancer [26,27]. As of yet, there is no method to
differentiate between these two types of cancers with certainty,
although suggestions based on the histology of adjacent stomach
tissue may be useful in future studies of EGJA [26].
Strengths of this analysis include the availability of individual
participant data which enabled harmonization of variables and
statistical models, as well as permitting flexibility of analysis. This
reduces the likelihood that the heterogeneity detected was a result
of differences in inclusion of covariates, modeling of covariates, or
choice of statistical parameters. The consortial approach enabled
generation of the largest dataset yet to permit assessment of the
association between gastroesophageal reflux and adenocarcinomas
of the esophagus. Limitations of this analysis include the moderate-
to-high heterogeneity associated with a majority of summary
estimates presented–cautious interpretation as to the magnitude of
these estimates is therefore warranted. It is important to note that
this pooled analysis assesses self-reported symptoms of heartburn
and regurgitation, yet exposure may not always elicit symptoms.
However, it has been shown that symptoms are indicative of
greater severity of acid reflux exposure [28]. Moreover, to
differentiate between infrequent heartburn/regurgitation, which
is quite common in most western populations, and symptoms
which are more likely to reflect pathologic reflux, we defined
recurrent exposure as being of a frequency of at least weekly.
Related to this point is the fact that the presence of Barrett’s
esophagus–a condition associated with gastroesophageal reflux
and the recognized precursor to EA–is thought to desensitize the
esophagus to such exposures. However, one would expect this to
bias results towards the null, as one would expect a higher
prevalence of Barrett’s esophagus in cases than population-based
controls. It is conceivable that study variability in symptom
exclusion period contributed to the moderate-to-high heterogene-
ity estimated, although the Australian Cancer Study–with the
longest symptom exclusion period–was not a major source of
heterogeneity. A final limitation is that case-control studies may be
affected by recall bias, with esophageal cancer patients more
accurately or possibly over-reporting reflux symptomatology
leading to over-estimated relationships.
In conclusion, our analysis of individual participant data from
the international BEACON consortium provides evidence for a
strong relationship between gastroesophageal reflux exposures and
adenocarcinomas of the esophagus, and indicates that longer
duration and increased frequency of reflux are both associated
with carcinogenic risk. Future studies should aim to ascertain
gastroesophageal reflux exposures across the life-course using
validated exposure assessment tools. In addition, studies are
needed to further elucidate the morphological, functional,
molecular and bacteriological mechanisms that link severe
gastroesophageal reflux disease to cancer.
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